

**CANADIAN GENERAL MEDICALCENTER  
COMPLEX COMPANY**

(A Saudi Joint Stock Company)

**INTERIM CONDENSED FINANCIAL STATEMENTS  
(UN-AUDITED) FOR THE THREE-MONTH  
PERIOD ENDED MARCH 31, 2026 AND  
INDEPENDENT AUDITOR'S REVIEW REPORT**

---

**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**  
(A Saudi Joint Stock Company)

**INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED) FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026  
WITH INDEPENDENT AUDITOR'S REVIEW REPORT**

---

<b>TABLE OF CONTENTS</b>	<b>PAGES</b>
Independent auditor's review report on the interim condensed financial statements	2
Interim condensed statement of financial position	3
Interim condensed statement of profit or loss and other comprehensive income	4
Interim condensed statement of changes in equity	5
Interim condensed statement of cash flows	6
Notes to the interim condensed financial statements	7 – 13

## INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED FINANCIAL STATEMENTS

**The Shareholders of  
Canadian General Medical Center Complex Company  
(A Saudi Joint Stock Company)**

### Introduction

We have reviewed the accompanying interim condensed statement of financial position of Canadian General Medical Center Complex Company - "Saudi Joint Stock Company" ("the Company") as of March 31, 2026, and the related interim condensed statements of profit or loss and other comprehensive income, changes in equity and cash flows for the three-month period then ended, and other explanatory notes. Management is responsible for the preparation and presentation of these interim condensed financial statements in accordance with International Accounting Standard 34 –Interim Financial Reporting" ("IAS 34") that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed financial statements based on our review.


### Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" that is endorsed in the Kingdom of Saudi Arabia. A review of interim condensed financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed financial statements are not prepared in all material respects, in accordance with IAS 34 that is endorsed in the Kingdom of Saudi Arabia.

**For Dr. Mohamed Al-Amri & Co.**



Ahmed Al Jumah  
Certified Public Accountant  
Registration No. 621



Dammam, on: 23 Dhul-Qi'dah, 1447 (H)  
Corresponding to: 10 May, 2026 (G)

**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**

(A Saudi Joint Stock Company)


**INTERIM CONDENSED STATEMENT OF FINANCIAL POSITION  
AS AT MARCH 31, 2026**

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)


	Notes	March 31, 2026 (Un-audited)	December 31, 2025 (Audited)
<b>ASSETS</b>			
<b>Non-current assets</b>			
Property and equipment	4	22,388,303	23,447,277
Right-of-use assets	5	5,555,708	6,054,306
<b>Total non-current assets</b>		<b>27,944,011</b>	<b>29,501,583</b>
<b>Current assets</b>			
Inventories		3,442,353	2,847,893
Trade receivables	6	61,095,486	59,249,948
Prepayments and other receivables		14,602,664	7,088,564
Investments at fair value through profit or loss (FVTPL)	7	24,802,999	30,115,550
Cash and cash equivalents		8,571,902	4,200,466
<b>Total current assets</b>		<b>112,515,404</b>	<b>103,502,421</b>
<b>TOTAL ASSETS</b>		<b>140,459,415</b>	<b>133,004,004</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
Share capital		77,000,000	77,000,000
Actuarial reserve		(1,783,678)	(1,472,351)
Retained earnings		17,401,738	20,522,863
Treasury shares	13	(79,175)	-
<b>Total equity</b>		<b>92,538,885</b>	<b>96,050,512</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Employees' benefits obligations		8,930,466	8,165,158
Lease liabilities	5	2,845,975	2,924,950
<b>Total non-current liabilities</b>		<b>11,776,441</b>	<b>11,090,108</b>
<b>Current liabilities</b>			
Trade and other payables		24,145,344	19,755,671
Short term loan	8	3,560,736	-
Due to a related party	10	3,066,910	964,764
Lease liabilities	5	2,829,151	3,090,258
Provision for zakat	9	2,541,948	2,052,691
<b>Total current liabilities</b>		<b>36,144,089</b>	<b>25,863,384</b>
<b>Total liabilities</b>		<b>47,920,530</b>	<b>36,953,492</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>140,459,415</b>	<b>133,004,004</b>

The accompanying notes from 1 to 17 form an integral part of these un-audited interim condensed financial statements.

**Chief Financial Officer**



**Chief Executive Officer**



-3-

**Chairman**



**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**

(A Saudi Joint Stock Company)

**INTERIM CONDENSED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026**

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

		<b>For the three-month period ended</b>	
	<u>Note</u>	<b>March 31, 2026</b> <b>(Un-audited)</b>	<b>March 31, 2025</b> <b>(Un-audited)</b>
Revenue	11	<b>38,043,638</b>	30,089,173
Cost of revenue		<b>(29,871,072)</b>	(21,244,005)
<b>Gross profit</b>		<b>8,172,566</b>	8,845,168
General and administrative expenses		<b>(3,917,928)</b>	(2,608,099)
Selling and marketing expenses		<b>(765,856)</b>	(790,755)
Reversal / (charge) for expected credit loss on trade receivables	6	<b>591,073</b>	(259,611)
<b>Operating profit</b>		<b>4,079,855</b>	5,186,703
Fair value changes of investments at FVTPL	7	<b>(312,551)</b>	2,944,063
Finance cost		<b>(239,172)</b>	(214,843)
Other income		-	87,709
<b>Profit before Zakat</b>		<b>3,528,132</b>	8,003,632
Zakat	9	<b>(489,257)</b>	(558,289)
<b>Net profit for the period</b>		<b>3,038,875</b>	7,445,343
<b>Other comprehensive loss</b>			
<i>Items that will not be reclassified to profit or loss in subsequent periods:</i>			
Loss on remeasurement of employees' benefits obligations		<b>(311,327)</b>	(570,869)
<b>Total comprehensive income for the period</b>		<b>2,727,548</b>	6,874,474
<b>Basic and diluted earnings per share</b>	15	<b>0.04</b>	0.10

The accompanying notes from 1 to 17 form an integral part of these un-audited interim condensed financial statements.


Chief Financial Officer



Chief Executive Officer



Chairman



## CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

### INTERIM CONDENSED STATEMENT OF CHANGES IN EQUITY FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

	<u>Share capital</u>	<u>Actuarial reserve</u>	<u>Retained earnings</u>	<u>Treasury shares</u>	<u>Total</u>
<b>For the three-month period ended March 31, 2025 (un-audited)</b>					
Balance at January 01, 2025	77,000,000	(856,463)	17,725,975	-	93,869,512
Net profit for the period	-	-	7,445,343	-	7,445,343
Other comprehensive loss	-	(570,869)	-	-	(570,869)
Total comprehensive income for the period	-	(570,869)	7,445,343	-	6,874,474
Dividend (note 14)	-	-	(3,850,000)	-	(3,850,000)
Balance at March 31, 2025	<u>77,000,000</u>	<u>(1,427,332)</u>	<u>21,321,318</u>	<u>-</u>	<u>96,893,986</u>
<b>For the three-month period ended March 31, 2026 (un-audited)</b>					
Balance at January 01, 2026	<b>77,000,000</b>	<b>(1,472,351)</b>	<b>20,522,863</b>	<b>-</b>	<b>96,050,512</b>
Net profit for the period	<b>-</b>	<b>-</b>	<b>3,038,875</b>	<b>-</b>	<b>3,038,875</b>
Other comprehensive loss	<b>-</b>	<b>(311,327)</b>	<b>-</b>	<b>-</b>	<b>(311,327)</b>
Total comprehensive income for the period	<b>-</b>	<b>(311,327)</b>	<b>3,038,875</b>	<b>-</b>	<b>2,727,548</b>
Dividend (note 14)	<b>-</b>	<b>-</b>	<b>(6,160,000)</b>	<b>-</b>	<b>(6,160,000)</b>
Buy back of treasury shares (note 13)	<b>-</b>	<b>-</b>	<b>-</b>	<b>(79,175)</b>	<b>(79,175)</b>
Balance at March 31, 2026	<u><b>77,000,000</b></u>	<u><b>(1,783,678)</b></u>	<u><b>17,401,738</b></u>	<u><b>(79,175)</b></u>	<u><b>92,538,885</b></u>

The accompanying notes from 1 to 17 form an integral part of these un-audited interim condensed financial statements.

**Chief Financial Officer**

**Chief Executive Officer**

**Chairman**

# CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

## INTERIM CONDENSED STATEMENT OF CASH FLOWS FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

	For the three-month period ended	
	March 31,2026 (Un-audited)	March 31,2025 (Un-audited)
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Net profit before zakat	3,528,132	8,003,632
<i>Adjustments for non-cash items:</i>		
Depreciation of property and equipment	1,161,049	612,092
Depreciation on right-of-use assets	751,650	630,702
Employees' benefits obligations – provision	397,928	383,449
Finance cost	239,172	214,843
Gain on disposal of property and equipment	-	(8,696)
(Reversal) / charge for expected credit loss on trade receivables	(591,073)	259,611
Fair value changes of investments at FVTPL	312,551	(2,944,063)
	<b>5,799,409</b>	<b>7,151,570</b>
<b>Changes in working capital</b>		
Inventories	(594,460)	(2,353,401)
Trade receivables	(1,254,465)	(8,064,980)
Prepayments and other receivables	(2,514,100)	(58,163)
Due from a related party	-	(86,180)
Trade and other payables	(1,778,027)	117,964
Due to a related party	2,102,146	458,529
<b>Cash generated from / (used in) operations</b>	<b>1,760,503</b>	<b>(2,834,661)</b>
Employees' benefits obligations paid	(55,834)	(290,959)
<b>Net cash generated from / (used in) operating activities</b>	<b>1,704,669</b>	<b>(3,125,620)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchases of investments at FVTPL	-	(35,318,854)
Proceeds from sale of investments at FVTPL	-	35,331,196
Purchases of property and equipment	(102,075)	(36,296)
Proceeds from disposal of property and equipment	-	8,696
<b>Net cash used in investing activities</b>	<b>(102,075)</b>	<b>(15,258)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Net change in short-term loan	3,560,736	-
Repayment of lease liabilities	(712,719)	(528,833)
Purchase of treasury shares	(79,175)	-
<b>Net cash generated from / (used in) financing activities</b>	<b>2,768,842</b>	<b>(528,833)</b>
<b>Net change in cash and cash equivalents</b>	<b>4,371,436</b>	<b>(3,669,711)</b>
Cash and cash equivalents at beginning of the period	4,200,466	4,659,967
<b>Cash and cash equivalents at end of the period</b>	<b>8,571,902</b>	<b>990,256</b>
<b>Significant non-cash transactions:</b>		
Additions to right-of-use assets and lease liabilities (note 5)	253,052	-
Transfer from investments at FVTPL to other receivables (note 7)	5,000,000	-
Redemption and addition of investments at FVTPL (note 7)	30,115,550	-
Dividend payable (note 14)	6,160,000	-

The accompanying notes from 1 to 17 form an integral part of these un-audited interim condensed financial statements.

**Chief Financial Officer**



**Chief Executive Officer**

-6-  
Saad

**Chairman**



## CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY

(A Saudi Joint Stock Company)

### NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED) FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026

(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

#### 1. ORGANIZATION AND ACTIVITIES

Canadian General Medical Center Complex Company (the “Company”) is a Saudi joint stock company initially incorporated as a limited liability company registered in Dammam, Kingdom of Saudi Arabia under Commercial Registration No. 2050058605 dated Safar 13, 1429H (corresponding to February 20, 2008).

During the year 2020, the Company increased its share capital in several stages from ﷲ 2 million to ﷲ 77 million in addition to the entry of new shareholders. Later on, the shareholders of the Company decided to convert the Company from a Limited Liability Company to a Saudi Joint Stock Company under the same Commercial Registration. The Company obtained Ministerial approval for the said conversion on Jumada Al-Awwal 15, 1442 H, corresponding to December 30, 2020.

The Capital Market Authority, in its decision issued on Dhu al-Qi’dah 18, 1442 -H (corresponding to June 28, 2021), approved the Company’s request to register its shares for direct listing in the Parallel Market – Nomu.

In 2023, the Company’s Board of Directors resolved in their meeting held on July 6, 2023, to approve the transition of the Company’s listing from the Parallel Market (Nomu) to the Main Market, subject to obtaining the required regulatory approvals. On July 27, 2025, the Company submitted its application for the transition to the main market through the designated online portal provided by the relevant regulatory authorities.

On October 1, 2025 (corresponding to 09/04/1447H), the Saudi Exchange issued its resolution approving the Company’s request to transfer from the Nomu – Parallel Market to the Main Market. The Company is currently operating in the main market “TASI” of the Saudi Exchange.

The main activities of the Company are management of hospitals and health centers and trade in hospital tools and equipment and ambulances under License No. 10045 dated Jumada Al-Awwal 18, 1436 -H (corresponding to March 9, 2015).

The Company's registered office is located at Dammam, Kingdom of Saudi Arabia.

These interim condensed financial statements include the assets, liabilities and financial results of the Company and its following branches:

<b>Branch CR NO.</b>	<b>CR Date (Hijri)</b>	<b>CR Date (Gregorian)</b>	<b>City</b>
2050116858	03/11/1439-H	16/07/2018-G	Dammam
2055026411	22/04/1439-H	09/01/2018-G	Jubail
2059004078	08/06/1438-H	07/03/2017-G	Abqaiq
2051056715	15/05/1435-H	16/03/2014-G	Khobar
1009042659	18/11/1445-H	26/05/2024-G	Riyadh

#### 2. STATEMENT OF COMPLIANCE AND BASIS OF PREPARATION

These interim condensed financial statements have been prepared in accordance with International Accounting Standard 34 - “Interim Financial Reporting” (IAS-34) as endorsed in the Kingdom of Saudi Arabia and other standards and pronouncement that are issued by the Saudi Organization for Chartered and Professional Accountants (“SOCPA”).

These interim condensed financial statements do not include all the information and disclosures required in annual financial statements and therefore, should be read in conjunction with the Company's annual financial statements for the year ended December 31, 2025. In addition, results for the three-month period ended March 31, 2026 are not necessarily indicative of the results that may be expected for the financial year ending December 31, 2026.

The significant judgements made by management in applying the Company’s key sources of estimation uncertainty are similar to those described in the Company’s annual financial statements for the year ended December 31, 2025.

These interim condensed financial statements have been presented in Saudi Riyals (“ﷲ”) which is also the functional currency of the Company. All figures have been rounded off to the nearest Saudi Riyals, unless otherwise stated.

**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**  
(A Saudi Joint Stock Company)

**NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026**  
(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

---

**3. MATERIAL ACCOUNTING POLICIES**

The methods of computation and accounting policies adopted in the preparation of these interim condensed financial statements are consistent with those followed in the preparation of the Company's annual financial statements for the year ended December 31, 2025, except for the following accounting policy and amendments which applied for the first time in 2026.

**3.1 Treasury shares**

Own equity instruments that are reacquired (treasury shares) are recognised at cost and deducted from equity. No gain or loss is recognised in interim condensed statement of profit or loss and other comprehensive income on the purchase, sale, issue or cancellation of the Company's own equity instruments. Any difference between the carrying amount and the consideration, if reissued, is recognised in retained earnings.

**3.2 Standards and amendments issued and applied effective in current period**

There are no new standards issued, however, there are amendments to the following standards, which are effective in current period and have no material impact on Company's interim condensed financial statement;

<b>Amendments to standard</b>	<b>Description</b>	<b>Effective for annual years beginning on or after</b>
IFRS 9 & IFRS 7	Amendments - Classification and Measurement of Financial Instruments	January 1, 2026

---

**3.3 Impact of accounting standards issued but not yet effective**

There are a number of standards and interpretations which have been issued by the International Accounting Standards Board that are effective for periods beginning subsequent to December 31, 2026 (the date of the Company's next annual financial statements) that the Company has decided not to adopt early. These are explained in the Company's annual financial statements for the year ended December 31, 2025.

**4. PROPERTY AND EQUIPMENT**

	<b>March 31, 2026</b>	<b>December 31, 2025</b>
	<b>(Un-audited)</b>	<b>(Audited)</b>
Net book value at beginning of period / year	<b>23,447,277</b>	16,920,881
Additions during the period / year	<b>102,075</b>	9,356,533
Transfer from inventories	-	1,011,330
Depreciation charged during the period / year	<b>(1,161,049)</b>	(3,790,607)
Net book value of disposals during the period / year	-	(50,860)
Net book value at the end of the period / year	<b>22,388,303</b>	<b>23,447,277</b>

**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**  
(A Saudi Joint Stock Company)

**NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026**  
(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

**5. RIGHT OF USE ASSETS AND LEASE LIABILITIES**

The Company leases buildings and vehicles. The average term of the lease contracts ranges from 3 to 19 years.

**Right of use assets**

The following is a reconciliation of changes in right-of-use assets:

	<b>March 31, 2026</b>	December 31, 2025
	<b>(Un-audited)</b>	(Audited)
Net book value at beginning of period / year	<b>6,054,306</b>	7,288,505
Additions during the period / year	<b>253,052</b>	1,531,536
Adjustments	-	(38,009)
Depreciation charged during the period / year	<b>(751,650)</b>	(2,727,726)
Net book value at the end of the period / year	<b>5,555,708</b>	6,054,306

**Lease liabilities**

	<b>March 31, 2026</b>	December 31, 2025
	<b>(Un-audited)</b>	(Audited)
Balance at beginning of period / year	<b>6,015,208</b>	7,315,778
Additions during the period / year	<b>253,052</b>	1,531,536
Interest expense during the period / year	<b>119,585</b>	548,292
Adjustments	-	(40,694)
Paid during the period / year	<b>(712,719)</b>	(3,339,704)
Balance at the end of the period / year	<b>5,675,126</b>	6,015,208
Less: current portion	<b>(2,829,151)</b>	(3,090,258)
Non-current portion	<b>2,845,975</b>	2,924,950

**6. TRADE RECEIVABLES**

	<b>March 31, 2026</b>	December 31, 2025
	<b>(Un-audited)</b>	(Audited)
Trade receivables	<b>69,043,193</b>	67,788,728
Less: Expected credit loss	<b>(7,947,707)</b>	(8,538,780)
<b>Balance at the end of the period / year</b>	<b>61,095,486</b>	59,249,948

Trade receivables include an amount of ﷲ 18.4 million (2025: ﷲ 16.7 million) from a single customer.

**Movement of expected credit loss:**

	<b>March 31, 2026</b>	December 31, 2025
	<b>(Un-audited)</b>	(Audited)
Opening balance	<b>8,538,780</b>	6,671,401
Charged during the period / year	-	1,867,379
Reversed during the period / year	<b>(591,073)</b>	-
Closing balance	<b>7,947,707</b>	8,538,780

**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**  
(A Saudi Joint Stock Company)

**NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026**  
(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

**7. INVESTMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS (FVTPL)**

	<b>March 31, 2026</b>	December 31, 2025
	<b>(Un-audited)</b>	(Audited)
Balance at the beginning of the period / year	<b>30,115,550</b>	35,074,253
Redemptions during the period / year (note 7.1)	<b>(30,115,550)</b>	(35,331,196)
Additions during the period / year (note 7.1)	<b>30,115,550</b>	35,318,854
Fair value changes	<b>(312,551)</b>	(4,946,361)
Transfer to other receivables (note 7.2)	<b>(5,000,000)</b>	-
<b>Balance at the end of the period / year of investment at FVTPL</b>	<b>24,802,999</b>	30,115,550

**7.1** During the year 2024, the Company's management entered into a local Discretionary Portfolio Management ("DPM") agreement managed by the investment manager. The Board of Directors of the Company decided to transfer the Company's portfolio from the previous fund manager (Al Awwal Capital Fund) to the new fund manager (Al Rajhi Capital) during the three-month period ended March 31, 2026. The change of fund manager took place during the three-month period ended March 31, 2025 as well i.e, from Al Rajhi Awaed Fund to Al Awwal Capital fund.

The Company has elected to classify such investments at fair value through profit or loss (FVTPL). The value of said investments as at March 31, 2026 amounted to ﷲ 24,802,999 including cash amounted to ﷲ 837,386 (December 31, 2025: ﷲ 30,115,550 including cash amounted to of ﷲ 10,549,823).

**7.2** Further, during the three-month period ended March 31, 2026, the Company allocates / reserves ﷲ 5,000,000 to a separate account managed by the same fund manager i.e, Al Rajhi Capital for the purpose of buying back its own shares as mentioned in note 13 to these interim condensed financial statements. Accordingly, such amount has been reclassified from investments at FVTPL to “receivable from fund manager” shown under “prepayment and other receivables” in the interim condensed statement of financial position.

**8. SHORT TERM LOAN**

During the three-month period ended March 31, 2026, the Company entered into Tawarruq facility agreement with a local commercial bank in the Kingdom of Saudi Arabia. The facility is available to support the Company's working capital requirements.

During the three-month period ended March 31, 2026, the Company made drawdowns amounting to ﷲ 3.5 million under the facility. The drawdown balance is classified under current liabilities as it is payable within twelve months from the reporting period. The credit facility carries interest rates at SIBOR plus 4.5% per annum and is secured against a promissory note issued by the Company.

**9. PROVISION FOR ZAKAT**

**A- Movement of zakat provision**

	<b>March 31, 2026</b>	December 31, 2025
	<b>(Un-audited)</b>	(Audited)
Balance at beginning of the period / year	<b>2,052,691</b>	2,158,827
Charged during the period / year	<b>489,257</b>	2,045,973
Payments during the period / year	<b>-</b>	(2,152,109)
<b>Balance at the end of the period / year</b>	<b>2,541,948</b>	2,052,691

**B- Status of zakat assessment**

The Company has submitted its Zakat returns till the year ended December 31, 2025, and obtained the zakat certificate.

**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**  
(A Saudi Joint Stock Company)

**NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026**  
(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

**10. TRANSACTIONS AND BALANCES WITH RELATED PARTIES**

**10.A** It includes entities under common directorship, Board of Directors (executive and non-executive members) and the key management personnel of the Company. The following are the benefits paid or due to key management personnel for their services:

	<b>March 31, 2026</b>	March 31, 2025
	<b>(Un-audited)</b>	(Un-audited)
Short-term employee benefits and salaries	<b>1,124,569</b>	809,873
End of service benefits	<b>55,628</b>	113,740
	<b><u>1,180,197</u></b>	<u>923,613</u>

**10.B** The transactions with related parties during the period are as follows:

<b>Related party</b>	<b>Nature of transaction</b>	<b>March 31, 2026</b>	March 31, 2025
		<b>(Un-audited)</b>	(Un-audited)
Mehan for Human Resources (Entity under common directorship)	Recruitment services	<b>3,057,721</b>	1,179,915

**10.C Due to a related party**

	<b>March 31, 2026</b>	December 31, 2025
	<b>(Un-audited)</b>	(Audited)
Mehan for Human Resources	<b>3,066,910</b>	964,764
	<b><u>3,066,910</u></b>	<u>964,764</u>

**11. REVENUE**

	<b>March 31, 2026</b>	March 31, 2025
	<b>(Un-audited)</b>	(Un-audited)
Corporate customers – Medical clinic project contracts	<b>37,539,466</b>	29,606,018
Individual customers – Medical clinics sector	<b>504,172</b>	483,155
	<b><u>38,043,638</u></b>	<u>30,089,173</u>

	<b>March 31, 2026</b>	March 31, 2025
	<b>(Un-audited)</b>	(Un-audited)
At point in time	<b>3,970,176</b>	2,237,190
Over time	<b>34,073,462</b>	27,851,983
	<b><u>38,043,638</u></b>	<u>30,089,173</u>

**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**  
(A Saudi Joint Stock Company)

**NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026**  
(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

---

**12. SEGMENT REPORTING**

The Company has one segment, which is providing of medical services, The Company operates only in the Kingdom of Saudi Arabia and has no other geographical segment.

Transactions with major customers

The revenue from one of the major customers represent 35% of the total amount of the revenue for the period ended March 31, 2026 (March 31, 2025: 46%).

**13. TREASURY SHARES**

On June 15, 2025, the Extraordinary General Assembly approved the Company's purchase of a number of its own shares, with a maximum of 500,000 shares, for the purpose of allocating them to the Company's employees within the Employee Share Scheme. The purchase will be financed from the Company's own resources. The Board of Directors shall be authorized to complete the purchase within a maximum period of eighteen months from the date of the resolution of the Extraordinary General Assembly. The Company shall retain the purchased shares for a period not exceeding ten years from the date of the Extraordinary General Assembly's approval, as the maximum period for allocation to eligible employees. Upon the expiry of this period, the Company shall follow the procedures and regulations stipulated in the relevant laws and regulations.

During the three-month period ended March 31, 2026, the Company repurchased its own shares (13,866 number of shares) equivalent to ﷲ 79,175 from the open market. The repurchased shares are classified as treasury shares and are recognized as a deduction from equity as presented in the interim condensed statement of changes in equity.

The Company has not yet developed any share-based payment plan / scheme for its employees. Accordingly, no share-based payment arrangement has been recognized for the period.

**13.1 The movement in treasury shares during the period / year is as follows:**

	<b>March 31, 2026 (Un-audited)</b>	<b>December 31, 2025 (Audited)</b>
Balance at beginning of the period / year	-	-
Shares repurchased during the period	<b>79,175</b>	-
<b>Balance at the end of the period / year</b>	<b>79,175</b>	-

**14. DIVIDEND**

**For the period ended March 31, 2026**

On March 1, 2026, the Board of Directors of the Company, with the authorization of the shareholders in their meeting held on June 15, 2025, resolved to distribute cash dividend amounted to ﷲ 6,160,000 (ﷲ 0.08 per share) for the second half of the year 2025. The declared dividend during the period ended March 31, 2026 has not been paid yet and recorded in dividend payable under “Trade and other payables” in these interim condensed financial statements.

**For the period ended March 31, 2025**

On March 17, 2025, the Board of Directors of the Company, with the authorization of the shareholders in their meeting held on June 24, 2024, resolved to distribute cash dividend amounted to ﷲ 3,850,000 (ﷲ 0.05 per share) for the year 2024 and it was paid on May 25, 2025.

**CANADIAN GENERAL MEDICAL CENTER COMPLEX COMPANY**  
(A Saudi Joint Stock Company)

**NOTES TO THE INTERIM CONDENSED FINANCIAL STATEMENTS (UN-AUDITED)**  
**FOR THE THREE-MONTH PERIOD ENDED MARCH 31, 2026**  
(All amounts expressed in Saudi Riyals “ﷲ” unless otherwise mentioned)

---

**15. EARNINGS PER SHARE**

Basic earnings per share is calculated by dividing the profit for the period attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period. As a result of treasury shares (note 13), the outstanding weighted average number of ordinary shares post the treasury shares have been used for calculation of basic and diluted earnings per ordinary share.

Earnings per share are represented as follows:

	<b>For the three-months ended</b>	
	<b>March 31, 2026 (Un-audited)</b>	<b>March 31, 2025 (Un-audited)</b>
Net profit for the period	<b>3,038,875</b>	7,445,343
Weighted average number of shares for calculation for earnings per share	<b>76,996,728</b>	77,000,000
Basic and diluted earnings per share	<b>0.04</b>	0.10

**16. MEASUREMENT OF FAIR VALUE**

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, on the assumption that market participants act in their economic best interest. All assets and liabilities that are measured at fair value or whose fair value is disclosed in the interim condensed financial statements are classified according to the scope of the fair value hierarchy shown below:

- Level 1: Quoted (unadjusted) prices quoted in active markets for assets or liabilities that are identical to those being measured.
- Level 2: The inputs that can be observed or monitored for the asset or liability, directly or indirectly, other than the published prices included within the first level.
- Level 3: Inputs that cannot be observed for the asset or liability

The Company believes that the carrying values of its financial assets and financial liabilities as of March 31, 2026, and March 31, 2025 approximate their fair values. The investments measured at fair value through profit or loss represent investments in equity securities traded in active market and are classified at Level 1 of the fair value hierarchy.

**17. APPROVAL OF THE INTERIM CONDENSED FINANCIAL STATEMENTS**

These interim condensed financial statements were approved by the Board of Directors of the Company on May 5, 2026.